Anti-CTLA-4 Antibody (Ipilimumab Biosimilar)

Cat. No. AB50

Description

Reactivities	Human/Cynomolgus
Target	CTLA-4
Isotype	Human IgG1-Kappa
Conjugation	Unconjugated
ExpressSystem	HEK293
Applications	ELISA
MolecularWeight	51.4 kDa and 23 kDa.
Recommended Dilution Buffer	PBS (pH 7.4), contains no stabilizers or preservatives.
Purification	protein A
Sterility	0.2 μM filtered
Endotoxin	Less than 1 EU per μg by the LAL method.
Purity	> 95% as determined by Bis-Tris PAGE
	> 95% as determined by HPLC

Formulation and Storage

Formulation	PBS, 10% glycerol (pH 7.4)
Storage	Valid for 12 months from date of receipt when stored at -80°C.Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Background

CTLA-4 (cytotoxic T-lymphocyte-associated protein 4), also known as CD152, is a protein receptor that, functioning as an immune checkpoint, downregulates immune responses.CTLA4 is constitutively expressed in regulatory T cells but only upregulated in conventional T cells after activation – a phenomenon which is particularly notable in cancers. It acts as an "off" switch when bound to CD80 or CD86 on the surface of antigen-presenting cells.

Assay Data

Bis-Tris PAGE



Ipilimumab Biosimilar on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

SEC-HPLC

Anti-CTLA-4 Antibody (Ipilimumab Biosimilar)

Cat. No. AB50

Assay Data



The purity of Ipilimumab Biosimilar is greater than 95% as determined by SEC-HPLC.

Anti-CTLA-4 Antibody (Ipilimumab Biosimilar)

Cat. No. AB50

Assay Data

ELISA Data



Immobilized Human CTLA-4, His Tag at 0.5μg/ml (100μl/well) on the plate. Dose response curve for Ipilimumab Biosimilar with the EC50 of 12.1ng/ml determined by ELISA.